Insider Monkey

FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug ...
Cure Today

FDA Grants Priority Review to Rusfertide for Polycythemia Vera

Priority review follows NDA acceptance for a first-in-class hepcidin mimetic in PV, supported by breakthrough therapy, orphan drug, and fast track designations. Rusfertide targets iron regulation to ...
Morningstar

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy ...

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal Study Submission Primarily ...
Morningstar

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...
Insider Monkey

Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best future stocks to buy for the next 5 years. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the ...